About Benitec Biopharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://benitec.com/
Frequently Asked Questions
What is the 52-week range for BNTC?
The 52-week high is $16.76 and the 52-week low is $9.255.
What is the P/E ratio for BNTC?
The P/E ratio data is currently unavailable.
What is the dividend yield for BNTC?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -34.82%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -20671.43%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.45.
Analyst Recommendation Trends
Wall Street analyst consensus for BNTC over the last few months:
Latest BNTC News
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)
Benitec Biopharma (BNTC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treatedA Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in OctoberAdditional interim clinical study results from the ongoing BB-301 Phase 1b/2a trial have been accepted for late-breaking
Benitec Biopharma Q4 EPS $(0.26), Inline
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 38.1 percent increase over losses of $(0.42) per share from the same period last year.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-26 | Friedman David Matthew | +35,000 | - | - |
| 2026-01-22 | Mates Sharon | +31,500 | - | - |
| 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC | +11,587 | $13.44 | $155,729 |
| 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC | +65,800 | $13.44 | $884,352 |
| 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | +2,516 | $13.1 | $32,960 |
| 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | +14,320 | $13.1 | $187,592 |
| 2025-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC | +7,400 | $12.85 | $95,090 |
| 2025-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC | +42,600 | $12.85 | $547,410 |
| 2025-12-22 | SUVRETTA CAPITAL MANAGEMENT, LLC | +2,892 | $12.08 | $34,935 |
| 2025-12-22 | SUVRETTA CAPITAL MANAGEMENT, LLC | +16,650 | $12.08 | $201,132 |
| 2025-12-19 | SUVRETTA CAPITAL MANAGEMENT, LLC | +2,434 | $11.48 | $27,942 |
| 2025-12-19 | SUVRETTA CAPITAL MANAGEMENT, LLC | +13,950 | $11.48 | $160,146 |
| 2025-12-18 | SUVRETTA CAPITAL MANAGEMENT, LLC | +1,515 | $11.24 | $17,029 |
| 2025-12-18 | SUVRETTA CAPITAL MANAGEMENT, LLC | +8,700 | $11.24 | $97,788 |
| 2025-12-01 | Mehta Kishan | +35,000 | - | - |
| 2025-12-01 | Francis Peter | +35,000 | - | - |
| 2025-12-01 | Mates Sharon | +3,500 | - | - |
| 2025-12-01 | Smith Edward F | +35,000 | - | - |
| 2025-12-01 | BUCHI J KEVIN | +35,000 | - | - |
| 2025-11-18 | Mukadam Sophie | +500,000 | - | - |
| 2025-11-18 | Banks Jerel A. | +450,000 | - | - |
| 2025-11-18 | Boston Megan | +200,000 | - | - |
| 2025-11-07 | SUVRETTA CAPITAL MANAGEMENT, LLC | +751,111 | $13.5 | $10,139,999 |
| 2025-11-07 | SUVRETTA CAPITAL MANAGEMENT, LLC | +730,370 | $13.5 | $9,859,995 |
| 2025-11-05 | Mates Sharon | +28,517 | - | - |